ERBB2 and neoplasm: The results highlight that <i>HER2</i> amplification extends beyond conventional tumor types and enables the identification, via CGP testing, of non-traditional tumor subsets (cancers other than breast and gastric cancer), including rare cancers, that could be candidates for <i>HER2</i>-targeting therapy such as trastuzumab deruxtecan in Japan.